Webinar presentations: Ardeschir Ghofrani (PRO) vs Hiromi Matsubara (CON) on Riociguat should be given to all CTEPH patients, regardless of timing of PEA/BPA, Systematic follow-up of patients following acute pulmonary embolism is associated with an increased incidence of CTEPH and less severe disease, Charlotte Durrington, Women and CTEPH: The special meaning of BPA, Alejandro Cruz-Utrilla, G protein-coupled receptor expression from single cell RNA sequencing in CTEPH, Gayathri Viswanathan, Study of the antifibrotic action of JAK inhibitors for the prevention and treatment of CTEPH, Andrei Karpov, Unilateral chronic thromboembolic pulmonary disease: Do they benefit from surgery? Farid Rashidi

Webinar presentations

• Looking beyond the hype: Applied AI and machine learning in translational medicine, Dennis Wang
• Computational network pharmacology in cardiovascular disease – leveraging big data, Joseph Loscalzo
• Utilizing artificial intelligence to screen and diagnose iPAH, David Kiely
• Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood, Sokratis Kariotis
• Transcriptomic characterization of Pulmonary arterial hypertension on pathway level, Yajing Ji 

• When should a PH patient be considered for lung transplant? John Granton 
• Atrial septum defect creation or mechanical support for end-stage PAH Erika Rosenzweig 
• Lung and Heart-lung Transplant in 2021 – how well do PAH patients do? Eugene Golts
• Pluripotent stem cell-based approaches and the future of artificial lungs Ulrich Martin
• Timing and extent of ventricular reverse remodelling after lung transplant for PH Ryan Tedford 

• MicroRNAs and IncRNAs in right heart hypertrophy and failure Francois Potus
• LncRNA as biomarkers/therapeutic agents for pulmonary diseases - prospective view Stephen Chen 
• Epigenomics in pulmonary vascular remodelling Soni Savai-Pullamsetti 
• Multiomic tools for single cell analysis Herbert Schiller
• Proteomics: From discovery research toward the clinic - novel AI perspectives? Christopher Rhodes 

• Role of notch1 in experimental pulmonary hypertension Ralph Schermuly
• Notch-BMPR interactions in endothelium in PAH Marlene Rabinovitch
• Notch3 is a driver and biomarker for PAH Patricia Thistlethwaite 
• Notch3 lineage and pulmonary vasculopathy Maya Kumar 

• A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH, Peter Dorfmüller
• Remnants of lost pulmonary vasculature may be re-engaged in PAH, Duncan Stewart
• Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs, David Systrom
• Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs, Roham Zamanian

• The right ventricle in HFpEF, Marco Guazzi
• Genetic aspects in group2 PH, Mark Toshner 
• Exercise haemodynamics in heart failure: what can we learn from invasive CPET? Gabor Kovacs 
• Systemic consequences and interorgan cross-talk in heart failure and PH, Stephan Rosenkranz
• The natriuretic peptide Clearance receptor selectively causes right ventricular dysfunction in a model of pulmonary hypertension and heart failure with preserved ejection fraction, Vineet Agrawal 
• N-Lysine methyltransferase Smyd2-mediated HIF-1A stabilization plays a protective role in RV hypertrophy, Swathi Veeroju

• Update from the Fleischner Society Task Force for imaging in pulmonary hypertension, Martine Rémy-Jardin
• Molecular imaging of pulmonary vascular disease using microvascular endothelial cell ligands, Jocelyn Dupuis
• MRI to assess pulmonary vascular changes and PH progression, Jens Vogel-Claussen
• Xenon magnetic resonance imaging signatures of PH, Sudarshan Rajagopal 
• Synchrotron-based phase contrast micro-CT imaging of pulmonary vascular disease in human tissue and animal models, Karin Tran-Lundmark 

• Therapeutically targeting endothelial cell metabolic dysfunction in pulmonary arterial hypertension with apigenin, Iona Cuthbertson
• Epigenome-wide profiling uncovers novel gene regulatory networks in human pulmonary arterial hypertension, Prakash Chelladurai
• Implication of the histone methyltransferase “g9a” in pulmonary arterial hypertension, Charifa Awada 
• Perinatal exposure to serotonin re-uptake inhibitor causes mild pulmonary hypertension in adult female rats, Barbora Kaftanová 
• Endothelial overexpression of sirt3 protects the metabolic etiology in PAH, Anandharajan Rathinasabapath
• Axl is a novel modulator of bone morphogenetic protein receptor 2 in pulmonary arterial hypertension, Tatyana Novoyatleva 
• Equivalent outcomes for hereditary and idiopathic pulmonary arterial hypertension in children; an analysis from a national Australian registry, Katherine Kearney Graham 
• Effect of macitentan across prognostic age groups in patients with pulmonary arterial hypertension (PAH), Richard Channick
• Validation of artificial intelligence artery-vein Classification for Contrast CT imaging in PH subjects, Pietro Nardelli
• Efficacy in patient subgroups in the INCREASE Trial, a phase III Trial to evaluate inhaled Treprostinil in patients with pulmonary hypertension due to parenchymal Lung Disease, Victor Tapson
• Acetazolamide and high altitude pulmonary edema prevention, Erik Swenson 
• Telomeric Tankyrases: a novel and propitious target to ameliorate the maladaptation phenomena at heights, Manjula Miglani 

• SARS-1, MERS, SARS-2 and more: are coronavirus infections an ubiquitous part of our lives? Albert Osterhaus
• Endothelitis and aberrant angiogenesis – mechanisms of COVID-19 induced vascular injury, Danny Jonigk
• Venous thromboembolism in COVID-19: Prevalence and clinical picture, Stavros Konstantinides
• ACE-II receptors – Modulation of PVD in COVID-19? Anna Hemnes
• Tricuspid regurgitation, as proxy for acute pulmonary hypertension, and its association with short-term outcome in severe Covid-19, Claes Frostell 
• Venous and arterial thromboembolism in COVID-19: a systematic review with meta-analysis, Vicky Mai